Health Catalyst, Inc. (2YP.F)
| Previous Close | 5.55 |
| Open | 5.20 |
| Bid | 5.60 x N/A |
| Ask | 5.70 x N/A |
| Day's Range | 5.20 - 5.20 |
| 52 Week Range | 5.15 - 12.70 |
| Volume | |
| Avg. Volume | 0 |
| Market Cap | 304.528M |
| Beta (5Y Monthly) | 1.29 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.95 |
| Earnings Date | May 09, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 66.00 |
GlobeNewswireHealth Catalyst to Announce First Quarter 2024 Operating Results and Host Conference Call on Thursday, May 9, 2024
SALT LAKE CITY, April 24, 2024 (GLOBE NEWSWIRE) -- Health Catalyst, Inc. ("Health Catalyst", Nasdaq: HCAT), a leading provider of data and analytics technology and services to healthcare organizations, will release its first quarter 2024 operating results on Thursday, May 9, 2024, after market close. In conjunction, the company will host a conference call to review the results at 5 p.m. E.T. on the same day. Conference Call Details The conference call can be accessed by dialing 800-267-6316 for
ZacksDown -24.71% in 4 Weeks, Here's Why You Should You Buy the Dip in Health Catalyst (HCAT)
Health Catalyst (HCAT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
ZacksWall Street Analysts Think Health Catalyst (HCAT) Could Surge 53.65%: Read This Before Placing a Bet
The mean of analysts' price targets for Health Catalyst (HCAT) points to a 53.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
